share_log

Genocea Biosciences (NASDAQ:GNCA) Now Covered by StockNews.com

kopsource ·  Aug 19, 2022 05:42

Stock analysts at StockNews.com assumed coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Rating) in a report issued on Wednesday. The firm set a "sell" rating on the biotechnology company's stock.

GNCA has been the subject of a number of other reports. HC Wainwright downgraded Genocea Biosciences from a "buy" rating to a "neutral" rating in a research report on Friday, April 29th. Stifel Nicolaus lowered Genocea Biosciences from a "buy" rating to a "hold" rating in a research note on Friday, April 29th.

Get Genocea Biosciences alerts:

Genocea Biosciences Price Performance

Genocea Biosciences stock opened at $0.01 on Wednesday. The firm has a 50 day moving average of $0.01 and a 200 day moving average of $0.47. Genocea Biosciences has a 12-month low of $0.01 and a 12-month high of $2.20. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.35 and a quick ratio of 1.35.

Insiders Place Their Bets

In other Genocea Biosciences news, Director Ali Behbahani sold 4,445,093 shares of the firm's stock in a transaction dated Wednesday, May 25th. The stock was sold at an average price of $0.08, for a total value of $355,607.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, major shareholder Paul Edward Walker sold 5,931,843 shares of Genocea Biosciences stock in a transaction dated Tuesday, May 24th. The stock was sold at an average price of $0.07, for a total transaction of $415,229.01. Following the completion of the sale, the insider now owns 4,445,093 shares of the company's stock, valued at $311,156.51. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ali Behbahani sold 4,445,093 shares of Genocea Biosciences stock in a transaction that occurred on Wednesday, May 25th. The shares were sold at an average price of $0.08, for a total value of $355,607.44. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 10,537,612 shares of company stock valued at $781,461. 1.61% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Genocea Biosciences stock. Commonwealth Equity Services LLC grew its holdings in Genocea Biosciences, Inc. (NASDAQ:GNCA – Get Rating) by 49.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 31,981 shares of the biotechnology company's stock after purchasing an additional 10,576 shares during the period. Commonwealth Equity Services LLC owned approximately 0.06% of Genocea Biosciences worth $37,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 59.25% of the company's stock.

About Genocea Biosciences

(Get Rating)

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.

Featured Stories

  • Get a free copy of the StockNews.com research report on Genocea Biosciences (GNCA)
  • Institutional Support For TJX Companies May Cap Gains
  • If You Hate Speed Cameras, Then You'll Like Verra Mobility Stock
  • Is Sanofi A Buy, Despite Recent Stumbles?
  • Starbucks Stock, Is Brand Loyalty Enough Reason to Buy
  • BJ's Wholesale Club Pops, Will Costco Be Next?

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment